

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2020

Dietary glycaemic index, glycaemic load and head and neck cancer risk: A pooled analysis in an international consortium

Chun-Pin Chang
University of Utah

Jose P Zevallos
Washington University School of Medicine in St. Louis
et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Chang, Chun-Pin; Zevallos, Jose P; and et al, "Dietary glycaemic index, glycaemic load and head and neck cancer risk: A pooled analysis in an international consortium." *British Journal of Cancer*. 122, 6. 745 - 748. (2020).

https://digitalcommons.wustl.edu/open_access_pubs/9039

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.



BRIEF COMMUNICATION

Epidemiology

Dietary glycaemic index, glycaemic load and head and neck cancer risk: a pooled analysis in an international consortium

Chun-Pin Chang¹, Carlo La Vecchia², Diego Serraino³, Andrew F. Olshan⁴, Jose P. Zevallos⁵, Hal Morgenstern⁶, Fabio Levi⁷, Werner Garavello⁸, Karl Kelsey⁹, Michael McClean¹⁰, Chu Chen¹¹, Stephen M. Schwartz¹¹, Stimson Schantz¹², Guo-Pei Yu¹³, Paolo Boffetta^{14,15}, Mia Hashibe¹, Yuan-Chin Amy Lee¹, Maria Parpinel¹⁶, Livia S. A. Augustin^{17,18}, Federica Turati², Zuo-Feng Zhang¹⁹ and Valeria Edefonti²

High dietary glycaemic index (GI) and glycaemic load (GL) may increase cancer risk. However, limited information was available on GI and/or GL and head and neck cancer (HNC) risk. We conducted a pooled analysis on 8 case-control studies (4081 HNC cases; 7407 controls) from the International Head and Neck Cancer Epidemiology (INHANCE) consortium. We estimated the odds ratios (ORs) and 95% confidence intervals (CIs) of HNC, and its subsites, from fixed- or mixed-effects logistic models including centre-specific quartiles of GI or GL. GI, but not GL, had a weak positive association with HNC (OR_{Q4 vs. Q1} = 1.16; 95% CI = 1.02–1.31). In subsites, we found a positive association between GI and laryngeal cancer (OR_{Q4 vs. Q1} = 1.60; 95% CI = 1.30–1.96) and an inverse association between GL and oropharyngeal cancer (OR_{Q4 vs. Q1} = 0.78; 95% CI = 0.63–0.97). This pooled analysis indicates a modest positive association between GI and HNC, mainly driven by laryngeal cancer.

British Journal of Cancer (2020) 122:745–748; <https://doi.org/10.1038/s41416-019-0702-4>

BACKGROUND

Most head and neck cancers (HNCs) are attributed to tobacco smoking and/or alcohol drinking.¹ Diet has been suggested to play a role in HNC aetiology, with non-starchy vegetables and selected healthy dietary patterns being inversely related with HNC risk.²

Average daily glycaemic index (GI) ranks carbohydrate foods based on the postprandial blood glucose response; average glycaemic load (GL) estimates the impact of carbohydrate consumption using the GI, while taking into account the amount of carbohydrates that are consumed.³ Higher GI and GL are moderately associated with risk of several cancers,⁴ likely because of stimulation of insulin release and bioactivity of insulin-like growth factor-1, which has proliferative, angiogenic, anti-apoptotic and oestrogen stimulating properties.⁵

Only two studies^{6,7} have investigated the effect of GI and GL on HNC risk, with inconsistent findings; one of these studies⁶ reported results by sub-site, based, however, on a limited number of cases.

The objective of this paper is to assess the association of GI or GL with HNC and its subsites (i.e. oral cavity, oropharynx, hypopharynx and larynx) using pooled dietary data from eight case-control studies participating in the International Head and Neck Cancer Epidemiology (INHANCE) consortium.⁸

METHODS

Within data version 1.5 of the INHANCE dataset, information on GI and GL was available from 3 case-control studies. In addition, we calculated GI and/or GL intakes from study-specific food items and

¹Division of Public Health, Department of Family & Preventive Medicine, University of Utah School of Medicine, and Huntsman Cancer Institute, 375 Chipeta Way, Suite A, Salt Lake City, UT 84108, USA; ²Department of Clinical Sciences and Community Health, Università degli Studi di Milano, via Venezian, 1, 20133 Milano, Italy; ³Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, via Gallini, 2, 33081 Aviano, Italy; ⁴Department of Epidemiology, Gillings School of Global Public Health, Campus Box 7435, Chapel Hill, NC 27599, USA; ⁵Division of Head and Neck Surgical Oncology, Department of Otolaryngology/Head and Neck Surgery, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8115, St. Louis, MO 63110, USA; ⁶Departments of Epidemiology and Environmental Health Sciences, School of Public Health, and Department of Urology, Medical School, University of Michigan, 1415 Washington Heights, M5164 SPH-II, Ann Arbor, MI 48109-2029, USA; ⁷Institut Universitaire de Médecine Sociale et Préventive (IUMSP), Unisanté, University of Lausanne, Route de la Corniche 10, 1010 Lausanne, Switzerland; ⁸Department of Otorhinolaryngology, School of Medicine and Surgery, University of Milano-Bicocca, via Pergolesi, 33, 20052 Monza, Italy; ⁹Department of Epidemiology and Department of Laboratory Medicine and Pathology, Brown University, 70 Ship Street, Providence, RI 02912, USA; ¹⁰Boston University School of Public Health, 715 Albany St Talbot Building, Boston, MA 02118, USA; ¹¹Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA; ¹²New York Eye and Ear Infirmary, 310 East 14th Street, New York, NY 10003, USA; ¹³Department of Otolaryngology, School of Medicine, New York Medical College, Valhalla, New York, NY, USA; ¹⁴The Tisch Cancer Institute, Mount Sinai School of Medicine, 17 E 102 St 4th Floor Room 4-110, New York, NY 10029, USA; ¹⁵Department of Medical and Surgical Sciences, University of Bologna, via Massarenti, 9, 40138 Bologna, Italy; ¹⁶Department of Medicine, University of Udine, via Colugna, 50, 33100 Udine, Italy; ¹⁷Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", via Semmla, 53, 80131 Napoli, Italy; ¹⁸Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 61, Queen St. East, Toronto, ON M5C 2T2, Canada and ¹⁹Department of Epidemiology, UCLA Fielding School of Public Health, 71-225 CHSBox 951772, Los Angeles, CA 90095, USA
Correspondence: Valeria Edefonti (valeria.edefonti@unimi.it)

food composition databases for another five studies, giving a total of eight studies included in the analysis. Details on individual studies and data pooling methods have been previously described⁸ and are summarised in Supplementary Table S1. Informed consents and institutional review board approvals were obtained within the framework of the original studies.

Selection of subjects

Cases were included if their cancer had been originally classified as invasive cancer of the oral cavity, pharynx, larynx or unspecified oral cavity/pharynx. Corresponding controls from the original studies were included in the analysis. We excluded subjects with missing information on the site of origin of cancer, or GI or GL value, and those with missing or implausible (<500 or >5500 kcal/day) non-alcohol energy intake. Thus, our analysis included 11,488 subjects, with 4081 HNC cases and 7407 controls (4264 hospital-based and 3143 population-based controls). There were 810 oral cavity, 1172 oropharynx, 343 hypopharynx, 1338 larynx and 418 unspecified oral cavity/pharynx cancer cases.

Specification of variables

Study-specific food-frequency questionnaires (FFQs) and food composition tables allowed us to calculate individual values of GI and GL for the four studies lacking information on both the exposures [Los Angeles, Boston, Seattle (1985–1995) and Memorial Sloan Kettering Cancer Center (MSKCC) studies]. In detail, as described previously,⁹ the GI of a food was expressed as a percentage of the glycaemic response elicited by white bread as a standard food with a GI of 100. The average daily GI for each subject was computed by summing the products of the GI value of each food times the amount of available carbohydrates in that food consumed per day, divided by the total amount of available carbohydrates (g) consumed per day. The average daily GL (g) was calculated by summing the products of the GI value of each food times the amount of available carbohydrates in that food consumed per day, divided by 100. Each GL unit represents the equivalent of 1 g of carbohydrate from white bread. Therefore, we initially converted frequencies of consumption into servings/day and servings/day into grams/day; then, we assigned the corresponding GI to each food item and applied the previous formulas to derive individual GI and GL values. For the North Carolina (2002–2006) study, information on individual values of GL was originally provided to the INHANCE Consortium Coordinating Center. We estimated GI as 100 multiplied with GL and divided by total available grams of carbohydrate intake (Supplementary Material—text and Table S2 for GI/GL calculation and study-specific GI values).

Statistical analysis

Multiple logistic regression models were used to estimate the odds ratios (ORs) of HNC and the corresponding 95% confidence intervals (CIs) according to centre-specific quartiles of GI or GL among controls (Supplementary Tables S3 for descriptive statistics of GI and GL distributions). In the presence of heterogeneity of GI or GL intakes across centres, we used a random-slope logistic regression model, whereas a fixed-effects model was used otherwise.¹⁰ The models included the following potential confounders: age, sex, race/ethnicity, study centre, education, cigarette smoking intensity, cigarette smoking duration, cigar smoking status, pipe smoking status, alcohol drinking intensity and the product term of cigarette smoking and alcohol drinking intensities. For GI, models were further adjusted for energy intake without alcohol; for GL, models were further adjusted for energy intake without alcohol and carbohydrates. For both GI and GL models, we used centre-specific control-based quartiles of energy intake. Separate analyses were carried out by HNC subsites and in strata of selected covariates. In sensitivity analyses, we further adjusted for history of diabetes or excluded subjects with diabetes

(information available for 6 studies). Analyses were performed using the SAS software (version 9.4, SAS Institute, Cary, NC).

RESULTS

Characteristics of our sample were presented in Supplementary Table S4. The highest GI quartile category (Q4) was associated with a higher HNC risk (OR_{Q4 vs. Q1} = 1.16; 95% CI = 1.02–1.31, p_{trend} = 0.037, Table 1). Across HNC subsites, GI was associated with an increased laryngeal cancer risk (OR_{Q4 vs. Q1} = 1.60; 95% CI = 1.30–1.96, p_{trend} < 0.001), but excluding laryngeal cancer cases, the OR_{Q4 vs. Q1} was 1.01 (95% CI = 0.88–1.16, p_{trend} = 0.90) (data not shown). Little associations between GL and cancers of the oral cavity, hypopharynx and larynx were observed. An inverse association was found between oropharyngeal cancer risk and GL (OR_{Q4 vs. Q1} = 0.78; 95% CI = 0.63–0.97, p_{trend} = 0.009). Results did not materially change when excluding subjects with diabetes or when additionally adjusting models by diabetes history. No heterogeneity was observed in strata of covariates (Supplementary Table S5).

DISCUSSION

In this large dataset, we observed a positive association between GI and HNC risk, essentially driven by laryngeal cancer. GL was not associated with the risk of overall HNC or its subsites, except for a possible inverse association with oropharyngeal cancer.

Inconsistent associations of GI and GL with HNC risk may be partly due to differences in the underlying dietary patterns. Indeed, higher dietary GL is strongly associated with higher carbohydrate intakes, while a higher GI is also associated with lower intakes of dairy products, legumes, fruit and vegetables.¹¹ In line with this hypothesis, an overlapping INHANCE-based analysis including seven of the eight current studies showed a positive association of laryngeal cancer with an “Animal products and cereals” dietary pattern, which was simultaneously based on high-GI (e.g. cereals) and low-GL (e.g. meat) foods.¹⁰

Only two previous studies^{6,7} have examined the association between GI or GL and HNC risk, with one of them partially overlapping with the current dataset.⁶ An analysis⁶ of three Italian case-control studies on upper aero-digestive tract cancers reported a positive association with higher GI (OR_{Q5 vs. Q1} = 1.5; 95% CI = 1.1–2.0) and GL (OR_{Q5 vs. Q1} = 1.8; 95% CI = 1.1–2.9) in quintiles. Although in the same direction, the association was weaker with oral and pharyngeal cancers combined or laryngeal cancer.⁶ Findings from the National Institutes of Health–AARP Diet and Health Study (1239 HNC cases; 446,177 participants) reported a null association with GI and a possible inverse association with GL in women (OR_{Q5 vs. Q1} = 0.63; 95% CI = 0.34–1.19), in the absence of a clear dose-response relationship.⁷

Limitations of the current analyses included possible recall bias and non-differential misclassification of GI/GL quartiles. In addition, food items contributing to GI differed in part across regions (Supplementary Table S2). However, all our FFQs were either reproducible and valid or were modifications of existing FFQs, already tested for reproducibility and validity. We were able to adjust for major potential confounders and our large sample size provided the necessary statistical power to examine the association in HNC subsites and strata.⁸

In conclusion, findings from this large-scale pooled analysis support a positive effect of average daily GI on the risk of HNC, and in particular of laryngeal cancer.

ACKNOWLEDGEMENTS

The authors would like to thank Marta Rossi for her useful suggestions in performing the statistical analysis on GI and GL.

Table 1. Odds ratios (ORs)^a and 95% confidence intervals (CIs) of glycaemic index and glycaemic load on cancers of head and neck, oral cavity, oropharynx, hypopharynx and larynx.

	Head and neck cancer (No. cases = 3967, No. controls = 7250 ^b) OR (95% CI)	Oral cavity cancer (No. cases = 780, No. controls = 7250 ^b) OR (95% CI)	Oropharyngeal cancer (No. cases = 1151, No. controls = 7250 ^b) OR (95% CI)	Hypopharyngeal cancer (No. cases = 328, No. controls = 6866 ^b) OR (95% CI)	Laryngeal cancer (No. cases = 11,299, No. controls = 6443 ^b) OR (95% CI)
Glycaemic index					
I Quartile	Reference	Reference	Reference	Reference	Reference
II Quartile	1.04 (0.91, 1.18)	0.92 (0.70, 1.20)	0.93 (0.77, 1.13)	0.87 (0.61, 1.23)	1.33 (1.08, 1.65)
III Quartile	1.02 (0.90, 1.17)	1.08 (0.66, 1.75)	0.90 (0.74, 1.09)	0.95 (0.68, 1.35)	1.28 (1.04, 1.59)
IV Quartile	1.16 (1.02, 1.31)	1.21 (0.81, 1.81)	0.93 (0.76, 1.12)	0.84 (0.59, 1.20)	1.60 (1.30, 1.96)
P _{for linear trend}	0.037	0.63	0.40	0.46	<0.001
P _{heterogeneity} ^{c,d}	0.35	0.03	0.41	0.22	0.66
Glycaemic load					
I Quartile	Reference	Reference	Reference	Reference	Reference
II Quartile	0.94 (0.82, 1.07)	0.88 (0.70, 1.12)	0.91 (0.75, 1.11)	0.78 (0.54, 1.13)	0.95 (0.76, 1.18)
III Quartile	0.89 (0.78, 1.02)	0.86 (0.68, 1.10)	0.75 (0.61, 0.92)	0.74 (0.51, 1.09)	1.03 (0.83, 1.28)
IV Quartile	0.91 (0.79, 1.05)	0.89 (0.69, 1.15)	0.78 (0.63, 0.97)	0.84 (0.57, 1.22)	1.03 (0.82, 1.28)
P _{for linear trend}	0.15	0.37	0.009	0.41	0.63
P _{heterogeneity} ^{c,d}	0.52	0.30	0.97	0.24	0.68

International Head and Neck Cancer Epidemiology (INHANCE) consortium

^aModels adjusted for age, sex, race/ethnicity, study center, education level, center-specific control-based quartiles of energy intake (without alcohol for glycaemic index; without alcohol and carbohydrate for glycaemic load), cigarette smoking intensity (number of cigarettes per day), cigarette smoking duration, cigar smoking status, pipe smoking status, alcohol drinking intensity (number of drinks per day) and the product (interaction) term for cigarette smoking intensity and alcohol drinking intensity

^bThe number of controls differed across subsites because a few studies considered cancers of the oral cavity, oropharynx and hypopharynx only; therefore, they contributed to the analysis with fewer controls than those studies with all cancer subsites included (see Supplementary Table 4)

^cP-value for heterogeneity between study centers

^dBased on the likelihood ratio test of heterogeneity between study centers, we reported the fixed-effects estimates when P_{heterogeneity} > 0.1 and the mixed-effects estimates when P_{studies} < 0.1

AUTHOR CONTRIBUTIONS

C. Chang contributed to write, review and/or revision of the manuscript; Y.A.L. contributed to the acquisition of the pooled data; C. Chang contributed to the analysis, and V.E. performed statistical support; C.L.V., V.E., F.T. and Z.Z. contributed substantially to the interpretation of data and were involved in drafting and revising the manuscript; D.S., A.F.O., J.P.Z., Z.Z., H.M., C.L.V., F.L., W.G., K.K., M.M., C. Chen, S.M.S., S.S. and G.Y. conducted research and provided single-study databases; L.S.A.A. and M.P. provided advice on nutritional issues; P.B., Y.A.L. and M.H. are the INHANCE study coordinators; all authors approved the final version of the manuscript.

ADDITIONAL INFORMATION

Ethics approval and consent to participate The Informed consent and institutional review board approval were obtained within the framework of the original studies, according to the rules existing at the time of data collection. In addition, a central Institutional Review Board approval was obtained from the University of Utah, #42912.

Consent to publish Not applicable.

Data availability The dataset used and analysed during the current study is available from the corresponding author on reasonable request.

Competing interests The authors declare no competing interests.

Funding information The INHANCE Pooled Data Project was supported by grants from the National Institutes of Health (NIH), National Cancer Institute (NCI) [R03CA113157], and National Institute of Dental and Craniofacial Research (NIDCR) [R03DE016611]. Individual studies were funded by the following grants: (1) Italy multicenter study: Italian Association for Research on Cancer (AIRC), Italian League Against Cancer and Italian Ministry of Research; (2) North Carolina (2002–2006) study: NCI [R01CA90731–01] and National Institute of Environmental Health Sciences (NIEHS) [P30ES010126]; (3) Los Angeles study: NIH [P50CA090388, R01DA011386,

R03CA077954, T32CA009142, U01CA096134 and R21ES011667] and the Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center; (4) Swiss study: Swiss League against Cancer and the Swiss Research against Cancer/Oncosuisse [KFS-700, OCS-1633]; (5) Milan (2006–2009) study: AIRC and Italian Ministry of Education [PRIN 2009 X8YCBN]; (6) Boston study: NIH [R01CA078609 and R01CA100679]; (7) Seattle (1985–1995) study: NIH [R01CA048996 and R01DE012609]; (8) MSKCC study: NIH [R01CA051845].

Supplementary information is available for this paper at <https://doi.org/10.1038/s41416-019-0702-4>.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Anantharaman, D., Marron, M., Lagiou, P., Samoli, E., Ahrens, W., Pohlabein, H. et al. Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer. *Oral. Oncol.* **47**, 725–731 (2011).
2. Su, H. I., Sammel, M. D., Velders, L., Horn, M., Stankiewicz, C., Matro, J. et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. *Fertil. Steril.* **94**, 645–654 (2010).
3. Augustin, L. S., Kendall, C. W., Jenkins, D. J., Willett, W. C., Astrup, A., Barclay, A. W. et al. Glycemic index, glycemic load and glycemic response: an International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). *Nutr. Metab. Cardiovasc. Dis.* **25**, 795–815 (2015).
4. Turati, F., Galeone, C., Augustin, L. S. A., La Vecchia, C. Glycemic index, glycemic load and cancer risk: an updated meta-analysis. *Nutrients* **11**, pii: E2342, <https://doi.org/10.3390/nu11102342> (2019).

5. Biddinger, S. B. & Ludwig, D. S. The insulin-like growth factor axis: a potential link between glycemic index and cancer. *Am. J. Clin. Nutr.* **82**, 277–278 (2005).
6. Augustin, L. S., Gallus, S., Franceschi, S., Negri, E., Jenkins, D. J., Kendall, C. W. et al. Glycemic index and load and risk of upper aero-digestive tract neoplasms (Italy). *Cancer Causes Control*. **14**, 657–662 (2003).
7. George, S. M., Mayne, S. T., Leitzmann, M. F., Park, Y., Schatzkin, A., Flood, A. et al. Dietary glycemic index, glycemic load, and risk of cancer: a prospective cohort study. *Am. J. Epidemiol.* **169**, 462–472 (2009).
8. Edefonti, V., Hashibe, M., Parpinel, M., Turati, F., Serraino, D., Matsuo, K. et al. Natural vitamin C intake and the risk of head and neck cancer: a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Int. J. Cancer* **137**, 448–462 (2015).
9. Hu, J., La Vecchia, C., Augustin, L. S., Negri, E., de Groh, M., Morrison, H. et al. Glycemic index, glycemic load and cancer risk. *Ann. Oncol.* **24**, 245–251 (2013).
10. De Vito, R., Lee, Y. C. A., Parpinel, M., Serraino, D., Olshan, A. F., Zevallos, J. P. et al. Shared and study-specific dietary patterns and head and neck cancer risk in an International Consortium. *Epidemiology* **30**, 93–102 (2019).
11. Mendez, M. A., Covas, M. I., Marrugat, J., Vila, J. & Schroder, H. Glycemic load, glycemic index, and body mass index in Spanish adults. *Am. J. Clin. Nutr.* **89**, 316–322 (2009).